Literature DB >> 24965758

Targeted delivery of Dicer-substrate siRNAs using a dual targeting peptide decorated dendrimer delivery system.

Xiaoxuan Liu1, Cheng Liu2, Chao Chen3, Mélanie Bentobji4, Francine Azario Cheillan4, Jeanne Thomassin Piana4, Fanqi Qu5, Palma Rocchi6, Ling Peng7.   

Abstract

Small interfering RNAs (siRNA) are emerging as novel therapeutic agents, providing competent delivery systems that are available. Dendrimers, a special family of synthetic macromolecules, represent an exciting delivery platform by virtue of their well-defined dendritic structure and unique multivalency and cooperativity confined within a nanoscale volume. Here, we report a Dicer-substrate siRNA (dsiRNA) which, when delivered using a structurally flexible triethanolamine-core poly(amidoamine) dendrimer of generation 5 as the nanocarrier, gives rise to a much greater RNAi response than that produced with conventional siRNA. Further decoration of the dsiRNA/dendrimer complexes with a dual targeting peptide simultaneously promoted cancer cell targeting through interacting with integrins and cell penetration via the interaction with neuropilin-1 receptors, which led to improved gene silencing and anticancer activity. Altogether, our results disclosed here open a new avenue for therapeutic implementation of RNAi using dendrimer nanovector based targeted delivery. FROM THE CLINICAL EDITOR: This study demonstrates superior therapeutic properties of siRNA when combined with a dendrimer-based targeted nano-delivery system. Similar approaches may eventually gain clinical utility following additional studies determining safety and efficacy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dendrimer; Nanovector; Prostate cancer; Targeted delivery; siRNA

Mesh:

Substances:

Year:  2014        PMID: 24965758     DOI: 10.1016/j.nano.2014.05.008

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  8 in total

Review 1.  Recent advances in dendrimer-based nanovectors for tumor-targeted drug and gene delivery.

Authors:  Prashant Kesharwani; Arun K Iyer
Journal:  Drug Discov Today       Date:  2014-12-31       Impact factor: 7.851

2.  Blocking Stemness and Metastatic Properties of Ovarian Cancer Cells by Targeting p70S6K with Dendrimer Nanovector-Based siRNA Delivery.

Authors:  Jing Ma; Shashwati Kala; Susan Yung; Tak Mao Chan; Yu Cao; Yifan Jiang; Xiaoxuan Liu; Suzanne Giorgio; Ling Peng; Alice S T Wong
Journal:  Mol Ther       Date:  2017-11-16       Impact factor: 11.454

Review 3.  Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes.

Authors:  Kenneth Omabe; Clément Paris; François Lannes; David Taïeb; Palma Rocchi
Journal:  Pharmaceutics       Date:  2021-04-21       Impact factor: 6.321

Review 4.  Therapeutic efficacy of nanomedicines for prostate cancer: An update.

Authors:  Vinoth-Kumar Lakshmanan
Journal:  Investig Clin Urol       Date:  2016-01-11

Review 5.  Dendrimers Show Promise for siRNA and microRNA Therapeutics.

Authors:  Volha Dzmitruk; Evgeny Apartsin; Aliaksei Ihnatsyeu-Kachan; Viktar Abashkin; Dzmitry Shcharbin; Maria Bryszewska
Journal:  Pharmaceutics       Date:  2018-08-08       Impact factor: 6.321

Review 6.  Recent Advances in the Development of Exogenous dsRNA for the Induction of RNA Interference in Cancer Therapy.

Authors:  Tatiana S Golubeva; Viktoria A Cherenko; Konstantin E Orishchenko
Journal:  Molecules       Date:  2021-01-29       Impact factor: 4.411

Review 7.  Insights on prospects of nano-siRNA based approaches in treatment of Cancer.

Authors:  Rajat Goyal; Hitesh Chopra; Inderbir Singh; Kamal Dua; Rupesh K Gautam
Journal:  Front Pharmacol       Date:  2022-08-25       Impact factor: 5.988

8.  Downregulation of TLX induces TET3 expression and inhibits glioblastoma stem cell self-renewal and tumorigenesis.

Authors:  Qi Cui; Su Yang; Peng Ye; E Tian; Guoqiang Sun; Jiehua Zhou; Guihua Sun; Xiaoxuan Liu; Chao Chen; Kiyohito Murai; Chunnian Zhao; Krist T Azizian; Lu Yang; Charles Warden; Xiwei Wu; Massimo D'Apuzzo; Christine Brown; Behnam Badie; Ling Peng; Arthur D Riggs; John J Rossi; Yanhong Shi
Journal:  Nat Commun       Date:  2016-02-03       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.